COPD Trial, Recruiting NCT05829083 Sponsor: Larissa University Hospital Condition: COPD
Back to Copd

COPD Trial, Recruiting

NCT05829083
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People experiencing a sudden worsening of their COPD symptoms that goes beyond their normal day-to-day changes, and that has required a change in their medication.
  • People whose blood tests show a mild-to-moderate build-up of carbon dioxide in the blood, with specific measurements falling within a defined range (pH between 7.25 and 7.35, and carbon dioxide levels above 45 mmHg).

Who may not be able to join:

  • People whose long-term high carbon dioxide levels have suddenly worsened in a specific ongoing pattern (confirm with trial site).
  • People with serious facial deformities, facial burns, or a permanent blockage in their upper airway.
  • People who urgently need a breathing tube inserted, such as those who have had a cardiac or respiratory arrest, or whose level of consciousness has dropped very low.
  • People experiencing severe agitation or restlessness that cannot be adequately controlled with sedation.
  • People who have inhaled a large amount of fluid or food into their lungs.
  • People who are persistently unable to clear mucus or secretions from their airway.
  • People with severe instability in blood pressure or circulation that is not responding to fluids or medications.
  • People with serious irregular heart rhythms of certain types.
  • People with dangerously low oxygen levels in the blood.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Konstantinos Gourgoulianis, Ph.D., Larissa University Hospital

Phone: 6945661525

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Larissa University Hospital
Registry
ClinicalTrials.gov
Start date
18 July 2023
Est. completion
1 December 2025

Where this trial is recruiting

🇬🇷 Greece

Primary endpoints

Arterial PCO2

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov